SEC Form 4 · accession 0001610717-26-000388
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeff Cislini
Officer — General Counsel
Period of report
Aug 21, 2026
Accepted (ET)
Aug 25, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 21, 2026 | M | 29,680 | $18.56 | A | 86,201 | D | |
| Common StockF2 | Aug 21, 2026 | M | 26,600 | $21.61 | A | 112,801 | D | |
| Common StockF3,F2 | Aug 21, 2026 | S | 3,400 | $207.2363 | D | 109,401 | D | |
| Common StockF4 | Aug 21, 2026 | S | 17,323 | $208.3688 | D | 92,078 | D | |
| Common StockF5,F2 | Aug 21, 2026 | S | 25,817 | $209.2497 | D | 66,261 | D | |
| Common StockF6,F2 | Aug 21, 2026 | S | 2,540 | $210.2647 | D | 63,721 | D | |
| Common StockF7,F2 | Aug 21, 2026 | S | 4,500 | $211.3417 | D | 59,221 | D | |
| Common StockF8,F2 | Aug 21, 2026 | S | 3,314 | $212.0583 | D | 55,907 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $18.56 | Aug 21, 2026 | M | 29,680 | D | Mar 1, 2026 | Feb 29, 2032 | Common Stock | 29,680 | 0 | D |
| Stock Option (Right to Buy)F9 | $21.61 | Aug 21, 2026 | M | 26,600 | D | — | Aug 31, 2032 | Common Stock | 26,600 | 3,500 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
- F2Includes 43,514 restricted stock units.
- F3This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.